TARPLIN, DOWNS & YOUNG, LLC

Lobbying for HANSA BIOPHARMA · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $60,000.00 income · posted Apr 20, 2026

Lobbying activity 2

Health Issues

Kidney issues, access to innovation, rare disease issues, organ rejection

Budget/Appropriations

Federal budget issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.